Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Fineline Cube Apr 27, 2026
Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Fineline Cube Apr 27, 2026
Company Deals

Beijing Wantai Biological and Fujian Provincial CDC Collaborate on Vaccine Development and Public Health Initiatives

Fineline Cube Sep 14, 2024

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a leading biopharmaceutical company based in...

Company Deals

MGI Tech and Haihe Laboratory Deepen Collaboration with Introduction of CycloneSEQ-WT02

Fineline Cube Sep 14, 2024

MGI Tech Co., Ltd, a prominent gene sequencing company based in China, has disclosed a...

Company Deals

MGI Tech and Sequanta Technologies Launch Advanced DCS Lab to Accelerate Omics Research

Fineline Cube Sep 14, 2024

MGI Tech Co., Ltd, a leading gene sequencing specialist based in China, has entered into...

Policy / Regulatory

China Boosts Public Health Subsidies and Targets Weight Management in 2024

Fineline Cube Sep 14, 2024

The National Health Commission, Ministry of Finance, National Administration of Traditional Chinese Medicine, and National...

Policy / Regulatory

China’s NHSA and MOF Issue Notices to Enhance Cross-Regional Medical Treatment Direct Settlement

Fineline Cube Sep 14, 2024

The National Healthcare Security Administration (NHSA) and the Ministry of Finance (MOF) have issued two...

Policy / Regulatory

CDE Launches CARE Plan to Streamline Rare Disease Drug Development

Fineline Cube Sep 14, 2024

The Center for Drug Evaluation has unveiled the ‘Pilot Work Plan for Patient-Centered Action for...

Company

Moderna Inc. Announces Cost-Cutting Measures and Pipeline Realignment

Fineline Cube Sep 13, 2024

Moderna Inc. (NASDAQ: MRNA), a leading mRNA technology company based in the U.S., has announced...

Company Deals

Sino Biological and BioGeometry Broaden Partnership to Advance AI-Driven Drug Discovery

Fineline Cube Sep 13, 2024

Sino Biological (SHE: 301047), a leading biotech company in China, and BioGeometry have announced an...

Company Drug

Johnson & Johnson Submits Second NDA for Nipocalimab to Treat Generalized Myasthenia Gravis

Fineline Cube Sep 13, 2024

Johnson & Johnson (NYSE: JNJ), a leading healthcare company based in the U.S., has reported...

Company Drug

Keymed Biosciences’ IL-4Rα mAb Stapokibart Receives NMPA Approval for Atopic Dermatitis Treatment

Fineline Cube Sep 13, 2024

Keymed Biosciences Inc. (HKG: 2162), a biopharmaceutical company based in China, has announced that the...

Company Policy / Regulatory

South Korea’s MFDS Aims to Slash Drug Approval Times with New Innovation Plan

Fineline Cube Sep 13, 2024

South Korea’s Ministry of Food and Drug Safety (MFDS) has unveiled an ambitious plan to...

Company Deals Digital

Alibaba Health Forges Strategic Partnerships with Viatris and Chinese Pharma Companies for Digital Health Expansion

Fineline Cube Sep 13, 2024

Alibaba Health Information Technology Ltd (HKG: 0241), the health industry arm of Chinese e-commerce giant...

Company Deals

Shanghai Bao Pharmaceutical and Subsidiary Secure Commercialization Rights Deal for SJ02 with Organon China

Fineline Cube Sep 13, 2024

Shanghai Bao Pharmaceutical, a Chinese pharmaceutical company, along with its wholly-owned subsidiary Suzhou Centergene Pharmaceuticals,...

Company Deals

ChemPartner Pharmatech Enters Strategic Partnership with Malaysian Entities to Develop Innovative Drugs

Fineline Cube Sep 13, 2024

ChemPartner Pharmatech Co., Ltd (SHE: 300149), a leading pharmaceutical company based in China, has joined...

Company Deals

Nona Biosciences and Umoja Biopharma Join Forces to Develop In Vivo CAR-T Therapies

Fineline Cube Sep 13, 2024

Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic...

Company Deals

Beijing’s MoleculeMind Secures Series A Funding to Accelerate AI Protein Design Innovations

Fineline Cube Sep 13, 2024

MoleculeMind, a Beijing-based AI protein design platform, has reportedly secured a Series A financing round,...

General/Other

Leadership Shuffle at China’s National Health Commission: Liu Jinfeng Steps in as Deputy Director

Fineline Cube Sep 13, 2024

The Ministry of Human Resources and Social Security has announced key leadership changes within the...

Company Deals

Autobio Diagnostics Partners with MBL to Advance Microbial Mass Spectrometry Technology

Fineline Cube Sep 13, 2024

Autobio Diagnostics Co., Ltd (SHA: 603658), a prominent player in China’s in vitro diagnostic market,...

Company Medical Device

Yestar Healthcare’s 2024 Interim Report Reflects Impact of Volume-Based Procurement on Revenue

Fineline Cube Sep 13, 2024

Yestar Healthcare Holdings Co., Ltd., a leading distributor and service provider for in vitro diagnostic...

Company Drug

Sanofi’s Dupixent Shows Promise in Phase III Trials for Rare Skin Disease and Chronic Hives

Fineline Cube Sep 12, 2024

Sanofi (EPA: SAN; NASDAQ: SNY), a leading French pharmaceutical company, has announced positive results from...

Posts pagination

1 … 289 290 291 … 657

Recent updates

  • Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million
  • Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China
  • Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU
  • Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104
  • Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.